Last reviewed · How we verify
PYM50028
At a glance
| Generic name | PYM50028 |
|---|---|
| Sponsor | Phytopharm |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD) (PHASE2)
- Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease (PHASE2)
- Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PYM50028 CI brief — competitive landscape report
- PYM50028 updates RSS · CI watch RSS
- Phytopharm portfolio CI